CN107921086A - MrkA多肽、抗体及其用途 - Google Patents

MrkA多肽、抗体及其用途 Download PDF

Info

Publication number
CN107921086A
CN107921086A CN201680047771.3A CN201680047771A CN107921086A CN 107921086 A CN107921086 A CN 107921086A CN 201680047771 A CN201680047771 A CN 201680047771A CN 107921086 A CN107921086 A CN 107921086A
Authority
CN
China
Prior art keywords
mrka
seq
binding protein
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680047771.3A
Other languages
English (en)
Chinese (zh)
Inventor
王群
S.拉简
曾昭舜
J.黑布林克汤普森
林宏宇
C.K.斯托弗
M.彭妮妮
W.达尔阿夸
P.S.乔扈里
肖晓东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Vaccines Inc
Original Assignee
MedImmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Vaccines Inc filed Critical MedImmune Vaccines Inc
Publication of CN107921086A publication Critical patent/CN107921086A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201680047771.3A 2015-08-24 2016-08-23 MrkA多肽、抗体及其用途 Pending CN107921086A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562208975P 2015-08-24 2015-08-24
US62/208975 2015-08-24
US201562238828P 2015-10-08 2015-10-08
US62/238828 2015-10-08
PCT/US2016/048221 WO2017035154A1 (en) 2015-08-24 2016-08-23 Mrka polypeptides, antibodies, and uses thereof

Publications (1)

Publication Number Publication Date
CN107921086A true CN107921086A (zh) 2018-04-17

Family

ID=58100831

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680047771.3A Pending CN107921086A (zh) 2015-08-24 2016-08-23 MrkA多肽、抗体及其用途

Country Status (16)

Country Link
US (2) US20170073397A1 (enExample)
EP (1) EP3341004A4 (enExample)
JP (1) JP2018527924A (enExample)
KR (1) KR20180042300A (enExample)
CN (1) CN107921086A (enExample)
AU (1) AU2016313653A1 (enExample)
BR (1) BR112018003252A2 (enExample)
CA (1) CA2995387A1 (enExample)
CL (1) CL2018000357A1 (enExample)
CO (1) CO2018001985A2 (enExample)
HK (1) HK1252350A1 (enExample)
IL (1) IL257434A (enExample)
MX (1) MX2018001964A (enExample)
RU (1) RU2018107056A (enExample)
TW (1) TW201718626A (enExample)
WO (1) WO2017035154A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115838430A (zh) * 2022-07-08 2023-03-24 中国人民解放军陆军军医大学 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用
CN116813725A (zh) * 2023-07-06 2023-09-29 中国人民解放军陆军军医大学 肺炎克雷伯菌的FimA的抗原表位肽及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900027XA (en) * 2016-08-05 2019-02-27 Medimmune Llc Anti-o2 antibodies and uses thereof
WO2018075375A1 (en) 2016-10-19 2018-04-26 Medimmune, Llc Anti-o1 antibodies and uses thereof
JP2020525540A (ja) 2017-06-23 2020-08-27 ノソコミアル ヴァクスィーン コーポレイション 免疫原性組成物
CN119798389A (zh) * 2024-12-12 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010386A2 (en) * 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
CN102015754A (zh) * 2007-05-02 2011-04-13 英特塞尔股份公司 克雷伯菌（Klebsiella）抗原
CN102695791A (zh) * 2009-09-04 2012-09-26 伦敦卫生及热带医学学院 蛋白质糖基化

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
WO2005034733A2 (en) * 2003-10-08 2005-04-21 North Shore-Long Island Jewish Research Institute Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
WO2012058334A1 (en) * 2010-10-26 2012-05-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Morphology & protein specific reagents as diagnostics for neurodegenerative diseases
SMT202000542T1 (it) * 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010386A2 (en) * 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
CN102015754A (zh) * 2007-05-02 2011-04-13 英特塞尔股份公司 克雷伯菌（Klebsiella）抗原
CN102695791A (zh) * 2009-09-04 2012-09-26 伦敦卫生及热带医学学院 蛋白质糖基化

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHIA-HAN CHAN等: "Identification of Protein Domains on Major Pilin MrkA That Affects the Mechanical Properties of Klebsiella pneumoniae Type 3 Fimbriae", 《LANGMUIR》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115838430A (zh) * 2022-07-08 2023-03-24 中国人民解放军陆军军医大学 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用
CN116813725A (zh) * 2023-07-06 2023-09-29 中国人民解放军陆军军医大学 肺炎克雷伯菌的FimA的抗原表位肽及其应用

Also Published As

Publication number Publication date
HK1252350A1 (zh) 2019-05-24
CL2018000357A1 (es) 2018-07-20
JP2018527924A (ja) 2018-09-27
TW201718626A (zh) 2017-06-01
US20170073397A1 (en) 2017-03-16
AU2016313653A1 (en) 2018-04-12
CO2018001985A2 (es) 2018-11-22
IL257434A (en) 2018-04-30
RU2018107056A (ru) 2019-09-26
MX2018001964A (es) 2018-06-19
US20190062411A1 (en) 2019-02-28
EP3341004A1 (en) 2018-07-04
EP3341004A4 (en) 2019-05-15
WO2017035154A1 (en) 2017-03-02
BR112018003252A2 (pt) 2018-09-25
KR20180042300A (ko) 2018-04-25
CA2995387A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
US20240383969A1 (en) Anti-o1 antibodies and uses thereof
US20190062411A1 (en) Mrka polypeptides, antibodies, and uses thereof
US12312397B2 (en) Anti-O2 antibodies and uses thereof
CN112672788B (zh) 抗金黄色葡萄球菌凝集因子a(clfa)的抗体
CN106536551B (zh) 大肠杆菌特异性抗体序列
KR20170136637A (ko) 항-스타필로코커스 아우레우스 항체 배합 제제
HK1248576A1 (en) Mrka polypeptides, antibodies, and uses thereof
KR102490823B1 (ko) 탄저균 보호항원에 특이적인 인간화 항체 및 이의 제조방법
HK40009426A (en) Anti-o1 antibodies and uses thereof
HK40007861A (en) Anti-o2 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1248576

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180417

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1248576

Country of ref document: HK